Salvage Therapy in Patients with Glioblastoma: Is There any Benefit?

Cancer

Volumn 98, Issue 12, 2003, Pages 2678-2686

  Hau, Peter ^a   Baumgart, Ulrike ^a   Pfeifer, Katharina ^a   Bock, Anne ^a   Jauch, Tanya ^a   Dietrich, Jörg ^a,b   Fabel, Klaus ^a,c   Grauer, Oliver ^a   Wismeth, Caecilia ^a   Klinkhammer Schalke, Monika ^a   Allgäuer, Michael ^d   Schuierer, Gerhard ^e   Koch, Horst ^a   Schlaier, Juergen ^a   Ulrich, Winfried ^a   Brawanski, Alexander ^a   Bogdahn, Ulrich ^a   Steinbrecher, Andreas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d Notfallzentrum Krankenhaus der Barmherzigen Brüder   (Germany)

^e Bezirksklinikum Regensburg   (Germany)

Author keywords

Disease recurrence; Glioblastoma; Reintervention; Salvage therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; REOPERATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 0344236156     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11845     Document Type: Article

References (30)

1. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000;88:2887.
2. Davis FG, Freels S, Grutsch J, et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 1998;88:1-10.
3. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 1985;56:1106-1111.
4. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol. 1988;6:338-343.
5. Should SC, Burger PC, Mendeksohn DB, et al. Primary tumors of the brain and spinal cord. Boston: Butterworth-Heinemann, 1997:51-54.
6. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol. 2000;1:459-468.
7. DeAngelis LM, Burger PC, Green SB, et al. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol. 1998;44:691-695.
8. Stewart LA, for the Glioma Trial Metaanalysis Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
9. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol. 2000;27(Suppl 6):1-10.
10. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest. 1996;14:551-559.
11. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol. 1999;17:2572.
12. Weller M, Muller B, Koch R, Bamberg M, Krauseneck P. Neuro-Oncology Working Group of the German Cancer Society. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol. 2003;21:3276-3284.
13. Medical Research Council. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001;19:509-518.
14. Boiardi A. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56:1782.
15. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259-266.
16. Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
17. Fabel K, Dietrich J, Hau P, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer. 2001;92:1936-1942.
18. Fabel-Schulte K, Hau P, Dietrich J, et al. 13-cis-retinoic acid as a potential treatment in glioma patients who show stable disease after combined modality treatment [abstract]. Proc Am Soc Clin Oncol. 2000;36:A679.
19. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
20. Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol. 1999;42:303-305.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Lee ET. Statistical methods for survival data analysis. Belmont, CA: Lifetime Learning, 1980.
23. Mantel N. Ranking procedures for arbitrarily restricted observations. Biometrics. 1967;23:65-78.
24. Zar JH. Biostatistical analysis. Englewood Cliffs, NJ: Prentice Hall, 1984.
25. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
26. Young T, de Haes JC, Curran D, et al. Guidelines for assessing quality of life in EORTC clinical trials. Brussels: EORTC, 1999.
27. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of nitrogen mustard in the palliative treatment of carcinoma: with particular reference to bronchial carcinoma. Cancer. 1948;1:634-656.
28. Kappelle AC, Postma TI, Taphoorn MJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56:118-120.
29. Winger MI, Macdonald DR, Schold SC Jr, Cairncross JG. Selection bias in clinical trials of anaplastic glioma. Ann Neurol. 1989;26:531-534.
30. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-1382.